rs1114167647
Variant summary
Our verdict is Uncertain significance. The variant received 5 ACMG points: 5P and 0B. PP2PP3PS3_ModeratePM2_Supporting
This summary comes from the ClinGen Evidence Repository: NM_000314.8(PTEN):c.359C>A (p.Ala120Glu) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.1.0). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PS3_M: Functional studies supportive of a damaging effect on the gene or gene product. Score of this variant = -2.09 (<= -1.11) on a high throughput phosphatase assay (PMID:29706350).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PP3: REVEL score > 0.7 (score of this variant = 0.901).PM2_P: Absent in gnomAD. LINK:https://erepo.genome.network/evrepo/ui/classification/CA377482264/MONDO:0017623/003
Frequency
Consequence
NM_000314.8 missense
Scores
Clinical Significance
Conservation
Publications
- Cowden syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
 - PTEN hamartoma tumor syndromeInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
 - macrocephaly-autism syndromeInheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Genomics England PanelApp, Orphanet
 - renal cell carcinomaInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
 - leiomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
 - activated PI3K-delta syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
 - Bannayan-Riley-Ruvalcaba syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
 - Cowden diseaseInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
 - Lhermitte-Duclos diseaseInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
 - Proteus-like syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
 - glioma susceptibility 2Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
 
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 5 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| PTEN | NM_000314.8  | c.359C>A | p.Ala120Glu | missense_variant | Exon 5 of 9 | ENST00000371953.8 | NP_000305.3 | |
| PTEN | NM_001304717.5  | c.878C>A | p.Ala293Glu | missense_variant | Exon 6 of 10 | NP_001291646.4 | ||
| PTEN | NM_001304718.2  | c.-392C>A | 5_prime_UTR_variant | Exon 4 of 9 | NP_001291647.1 | 
Ensembl
Frequencies
GnomAD3 genomes  Cov.: 32 
GnomAD4 exome Cov.: 31 
GnomAD4 genome  Cov.: 32 
ClinVar
Submissions by phenotype
PTEN hamartoma tumor syndrome    Uncertain:2 
In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on PTEN protein function. ClinVar contains an entry for this variant (Variation ID: 428222). This missense change has been observed in individual(s) with clinical features of Cowden syndrome (PMID: 20600018, 21194675, 21659347). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces alanine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 120 of the PTEN protein (p.Ala120Glu). -
NM_000314.8(PTEN):c.359C>A (p.Ala120Glu) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.1.0). Please see a summary of the rules and criteria codes in the "PTEN ACMG Specifications Summary" document (assertion method column). PS3_M: Functional studies supportive of a damaging effect on the gene or gene product. Score of this variant = -2.09 (<= -1.11) on a high throughput phosphatase assay (PMID:29706350). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PP3: REVEL score > 0.7 (score of this variant = 0.901). PM2_P: Absent in gnomAD. -
Hereditary cancer-predisposing syndrome    Pathogenic:1 
The p.A120E variant (also known as c.359C>A), located in coding exon 5 of the PTEN gene, results from a C to A substitution at nucleotide position 359. The alanine at codon 120 is replaced by glutamic acid, an amino acid with dissimilar properties.<span style="background-color: initial;">This alteration has been reported in two unrelated individuals that met r<span style="background-color: initial;">elaxed International Cowden Consortium criteria (Heald B et al. Gastroenterology. 2010 Dec;139(6):1927-33;<span style="background-color: initial;">Tan MH et al. Am J Hum Genet. 2011 Jan 7;88(1):42-56).<span style="background-color: initial;">This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6,503 samples (13,006 alleles) with coverage at this position.<span style="background-color: initial;">To date, this alteration has been detected with an allele frequency of approximately 0.002% (greater than 51,000 alleles tested) in our clinical cohort.<span style="background-color: initial;">This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis.<span style="background-color: initial;">Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at